Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
Major pharmaceutical companies have largely abandoned antibiotic development programs despite the pressing public health need.
The antibiotic startup graveyard is instructive.
Achaogen went bankrupt in 2019 despite FDA approval for plasomycin.
Melinta Therapeutics filed for bankruptcy.
Aradime abandoned antibiotic development entirely.
The pattern is clear.
The market structure makes life-saving medicines commercially unviable.
The market failures are so significant, researchers had to start a social venture, FairBio, with philanthropic and government funding to generate a route to move AI-discovered antibiotics forward.
While AI can, and already is, reducing friction and cost in drug development, the biggest expenditures, clinical trials and market launch, remain controlled by regulators and payers, with no incentive to compromise.
Market forces may block antibiotics, but surely not promising cancer therapies.
Tenespamycin, which showed positive results in late-stage trials for multiple myeloma and breast cancer, tells a different story.
Very few promising molecules reach late-stage trials, and combined with encouraging data, the drug seemed prime for approval.
Instead, the study was closed prematurely for resource-based reasons.
Bristol-Myers Squibb offered no official explanation, but a lead investigator suspected, drug most likely was halted because tenespamycin is difficult to produce, and there's only limited time remaining before the drug's patent expires.
Combined, these factors would make further investment in the drug difficult to justify financially.
Killing the program was not an act of corporate malice, but a necessary balancing act, weighing the value of a portfolio of promising drugs against market forces.
without extended patent exclusivity.
Companies cannot justify the enormous costs of late-stage trials, FDA approval, and market launch, especially when other patented drugs compete internally for investment.
Tenespamycin isn't alone.
By some estimates,
Showing 841–860 of 1,653 · page 43 of 83
← Previous
Next →